The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Body Surface Area

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Body Surface Area


High impact information on Body Surface Area

  • RESULTS: Patients in the control group and the propranolol group were similar with respect to age, weight, percentage of total body-surface area burned, percentage of body-surface area with third-degree burns, and length of time from injury to metabolic study [6].
  • METHODS: Women with bulky stage IB cervical cancers (tumor, > or =4 cm in diameter) were randomly assigned to receive radiotherapy alone or in combination with cisplatin (40 mg per square meter of body-surface area once a week for up to six doses; maximal weekly dose, 70 mg), followed in all patients by adjuvant hysterectomy [7].
  • The degree of suppression of thyrotropin secretion tended to be greater in patients treated with higher doses of bexarotene (>300 mg per square meter of body-surface area per day) and in those with a history of treatment with interferon alfa [8].
  • The mean (+/-SD) creatinine clearance rate declined from 108+/-20 ml per minute per 1.73 m2 of body-surface area at base line to 74+/-16 ml per minute per 1.73 m2 at 5 years (P<0.001) and 74+/-14 ml per minute per 1.73 m2 at 10 years (P<0.001) [9].
  • Patients in the combined-treatment group received 125 cGy twice daily, for a total of 7000 cGy, and five days of treatment with 12 mg of cisplatin per square meter of body-surface area per day and 600 mg of fluorouracil per square meter per day during weeks 1 and 6 of irradiation [10].

Chemical compound and disease context of Body Surface Area


Biological context of Body Surface Area


Anatomical context of Body Surface Area


Associations of Body Surface Area with chemical compounds

  • Patients randomly assigned to group 1 received cisplatin (100 mg per square meter of body-surface area given intravenously on days 1 and 29) and vinblastine (5 mg per square meter given intravenously on days 1, 8, 15, 22, and 29) and then began radiation therapy on day 50 (60 Gy over a 6-week period) [26].
  • Within four weeks after surgery, six courses of intravenous cyclophosphamide (600 mg per square meter of body-surface area per course) plus either intraperitoneal cisplatin (100 mg per square meter) or intravenous cisplatin (100 mg per square meter) were administered at three-week intervals [27].
  • Each woman received an intramuscular dose of methotrexate (50 mg per square meter of body-surface area) [28].
  • Eighteen patients received one dose of doxorubicin (45 mg per square meter of body-surface area), and 97 received multiple doses totaling 228 to 550 mg per square meter (median, 360) [29].
  • The cells promoted a rapid and sustained hemopoietic recovery when transplanted after treatment with high-dose etoposide (1500 mg per square meter of body-surface area), ifosfamide (12 g per square meter), carboplatin (750 mg per square meter), and epirubicin (150 mg per square meter) [30].

Gene context of Body Surface Area

  • If they receive standard doses of thiopurine medications (for example, 75 mg/m2 body surface area per day), TPMT-deficient patients accumulate excessive thioguanine nucleotides in hematopoietic tissues, which leads to severe and possibly fatal myelosuppression [31].
  • Patients with greater than 30% body surface area burns had significantly reduced IL-2 production (p less than or equal to 0.05) until 60 days after injury, whereas those with smaller burns had reduced IL-2 production only at 20-29 and 30-39 days postburn [32].
  • The capacity for T cell proliferation and the expression of Tac antigen (IL-2 receptor) was assessed during the post-burn period in patients with injuries ranging from 5-68% total body surface area [33].
  • After rats underwent 30% total body surface area burn injury, they were injected with S-methylisothiourea (SMT, selective inducible NOS inhibitor), 7-nitronidazole (7-NI, selective neuronal NOS inhibitor), and nimesulide (NIM, selective COX-2 inhibitor), respectively [34].
  • Models of rhIGF-I dosing based upon body surface area (BSA) or initial IGFBP-3 resulted in predictable peak serum IGF-I levels (r = 0.78; p < 0.03) [35].

Analytical, diagnostic and therapeutic context of Body Surface Area


  1. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. Evans, W.E., Crom, W.R., Abromowitch, M., Dodge, R., Look, A.T., Bowman, W.P., George, S.L., Pui, C.H. N. Engl. J. Med. (1986) [Pubmed]
  2. Acyclovir halts progression of herpes zoster in immunocompromised patients. Balfour, H.H., Bean, B., Laskin, O.L., Ambinder, R.F., Meyers, J.D., Wade, J.C., Zaia, J.A., Aeppli, D., Kirk, L.E., Segreti, A.C., Keeney, R.E. N. Engl. J. Med. (1983) [Pubmed]
  3. Improved renal function in children with cystinosis treated with cysteamine. Markello, T.C., Bernardini, I.M., Gahl, W.A. N. Engl. J. Med. (1993) [Pubmed]
  4. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. Cohn, J.N., Levine, T.B., Olivari, M.T., Garberg, V., Lura, D., Francis, G.S., Simon, A.B., Rector, T. N. Engl. J. Med. (1984) [Pubmed]
  5. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Mease, P.J., Goffe, B.S., Metz, J., VanderStoep, A., Finck, B., Burge, D.J. Lancet (2000) [Pubmed]
  6. Reversal of catabolism by beta-blockade after severe burns. Herndon, D.N., Hart, D.W., Wolf, S.E., Chinkes, D.L., Wolfe, R.R. N. Engl. J. Med. (2001) [Pubmed]
  7. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. Keys, H.M., Bundy, B.N., Stehman, F.B., Muderspach, L.I., Chafe, W.E., Suggs, C.L., Walker, J.L., Gersell, D. N. Engl. J. Med. (1999) [Pubmed]
  8. Central hypothyroidism associated with retinoid X receptor-selective ligands. Sherman, S.I., Gopal, J., Haugen, B.R., Chiu, A.C., Whaley, K., Nowlakha, P., Duvic, M. N. Engl. J. Med. (1999) [Pubmed]
  9. Reversal of lesions of diabetic nephropathy after pancreas transplantation. Fioretto, P., Steffes, M.W., Sutherland, D.E., Goetz, F.C., Mauer, M. N. Engl. J. Med. (1998) [Pubmed]
  10. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. Brizel, D.M., Albers, M.E., Fisher, S.R., Scher, R.L., Richtsmeier, W.J., Hars, V., George, S.L., Huang, A.T., Prosnitz, L.R. N. Engl. J. Med. (1998) [Pubmed]
  11. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. Lipshultz, S.E., Lipsitz, S.R., Mone, S.M., Goorin, A.M., Sallan, S.E., Sanders, S.P., Orav, E.J., Gelber, R.D., Colan, S.D. N. Engl. J. Med. (1995) [Pubmed]
  12. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Gralla, R.J., Casper, E.S., Kelsen, D.P., Braun, D.W., Dukeman, M.E., Martini, N., Young, C.W., Golbey, R.B. Ann. Intern. Med. (1981) [Pubmed]
  13. Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide. Loehrer, P.J., Lauer, R., Roth, B.J., Williams, S.D., Kalasinski, L.A., Einhorn, L.H. Ann. Intern. Med. (1988) [Pubmed]
  14. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Warrell, R.P., Israel, R., Frisone, M., Snyder, T., Gaynor, J.J., Bockman, R.S. Ann. Intern. Med. (1988) [Pubmed]
  15. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Verdecchia, P., Schillaci, G., Guerrieri, M., Gatteschi, C., Benemio, G., Boldrini, F., Porcellati, C. Circulation (1990) [Pubmed]
  16. Thyroid hormone treatment after coronary-artery bypass surgery. Klemperer, J.D., Klein, I., Gomez, M., Helm, R.E., Ojamaa, K., Thomas, S.J., Isom, O.W., Krieger, K. N. Engl. J. Med. (1995) [Pubmed]
  17. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. Sharma, G.V., Burleson, V.A., Sasahara, A.A. N. Engl. J. Med. (1980) [Pubmed]
  18. Serum uric acid in essential hypertension: an indicator of renal vascular involvement. Messerli, F.H., Frohlich, E.D., Dreslinski, G.R., Suarez, D.H., Aristimuno, G.G. Ann. Intern. Med. (1980) [Pubmed]
  19. Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation. Gurney, H.P., Ackland, S., Gebski, V., Farrell, G. J. Clin. Oncol. (1998) [Pubmed]
  20. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. Krischer, J.P., Epstein, S., Cuthbertson, D.D., Goorin, A.M., Epstein, M.L., Lipshultz, S.E. J. Clin. Oncol. (1997) [Pubmed]
  21. Abnormal responses of myeloid progenitor cells to recombinant human colony-stimulating factors in congenital neutropenia. Kobayashi, M., Yumiba, C., Kawaguchi, Y., Tanaka, Y., Ueda, K., Komazawa, Y., Okada, K. Blood (1990) [Pubmed]
  22. Alterations of interferon production in a mouse model of thermal injury. Suzuki, F., Pollard, R.B. J. Immunol. (1982) [Pubmed]
  23. Parenteral nutrition with short- and long-chain triglycerides: triacetin reduces atrophy of small and large bowel mucosa and improves protein metabolism in burned rats. Karlstad, M.D., Killeffer, J.A., Bailey, J.W., DeMichele, S.J. Am. J. Clin. Nutr. (1992) [Pubmed]
  24. Left ventricular diastolic filling alterations in subjects with mitral valve prolapse: a Doppler echocardiographic study. Corrao, S., Scaglione, R., Arnone, S., Licata, G. Eur. Heart J. (1993) [Pubmed]
  25. Extremity hyperinsulinemia stimulates muscle protein synthesis in severely injured patients. Gore, D.C., Wolf, S.E., Sanford, A.P., Herndon, D.N., Wolfe, R.R. Am. J. Physiol. Endocrinol. Metab. (2004) [Pubmed]
  26. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. Dillman, R.O., Seagren, S.L., Propert, K.J., Guerra, J., Eaton, W.L., Perry, M.C., Carey, R.W., Frei, E.F., Green, M.R. N. Engl. J. Med. (1990) [Pubmed]
  27. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. Alberts, D.S., Liu, P.Y., Hannigan, E.V., O'Toole, R., Williams, S.D., Young, J.A., Franklin, E.W., Clarke-Pearson, D.L., Malviya, V.K., DuBeshter, B. N. Engl. J. Med. (1996) [Pubmed]
  28. Methotrexate and misoprostol to terminate early pregnancy. Hausknecht, R.U. N. Engl. J. Med. (1995) [Pubmed]
  29. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. Lipshultz, S.E., Colan, S.D., Gelber, R.D., Perez-Atayde, A.R., Sallan, S.E., Sanders, S.P. N. Engl. J. Med. (1991) [Pubmed]
  30. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. Brugger, W., Heimfeld, S., Berenson, R.J., Mertelsmann, R., Kanz, L. N. Engl. J. Med. (1995) [Pubmed]
  31. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Yates, C.R., Krynetski, E.Y., Loennechen, T., Fessing, M.Y., Tai, H.L., Pui, C.H., Relling, M.V., Evans, W.E. Ann. Intern. Med. (1997) [Pubmed]
  32. Inadequate interleukin 2 production. A fundamental immunological deficiency in patients with major burns. Wood, J.J., Rodrick, M.L., O'Mahony, J.B., Palder, S.B., Saporoschetz, I., D'Eon, P., Mannick, J.A. Ann. Surg. (1984) [Pubmed]
  33. Impairment of T cell activation in burn patients: a possible mechanism of thermal injury-induced immunosuppression. Teodorczyk-Injeyan, J.A., Sparkes, B.G., Mills, G.B., Peters, W.J., Falk, R.E. Clin. Exp. Immunol. (1986) [Pubmed]
  34. Roles of nitric oxide and prostaglandins in pathogenesis of delayed colonic transit after burn injury in rats. Gan, H.T., Chen, J.D. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) [Pubmed]
  35. Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children. Ferry, R.J., Cohen, P., Levitt Katz, L.E. Horm. Res. (2005) [Pubmed]
  36. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. Rosell, R., Gómez-Codina, J., Camps, C., Maestre, J., Padille, J., Cantó, A., Mate, J.L., Li, S., Roig, J., Olazábal, A. N. Engl. J. Med. (1994) [Pubmed]
  37. Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. Bosset, J.F., Gignoux, M., Triboulet, J.P., Tiret, E., Mantion, G., Elias, D., Lozach, P., Ollier, J.C., Pavy, J.J., Mercier, M., Sahmoud, T. N. Engl. J. Med. (1997) [Pubmed]
  38. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. Moreland, L.W., Baumgartner, S.W., Schiff, M.H., Tindall, E.A., Fleischmann, R.M., Weaver, A.L., Ettlinger, R.E., Cohen, S., Koopman, W.J., Mohler, K., Widmer, M.B., Blosch, C.M. N. Engl. J. Med. (1997) [Pubmed]
  39. Evaluation of xylose absorption as measured in blood and urine: a one-hour blood xylose screening test in malabsorption. Haeney, M.R., Culank, L.S., Montgomery, R.D., Sammons, H.G. Gastroenterology (1978) [Pubmed]
  40. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Yap, H.Y., Blumenschein, G.R., Schell, F.C., Buzdar, A.U., Valdivieso, M., Bodey, G.P. Ann. Intern. Med. (1981) [Pubmed]
WikiGenes - Universities